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was categorized according to WHO classifications. Total direct medical costs were 
assessed for transplantation in terms of charges and payments. Costs were stand-
ardized to 2012 U.S. dollars. Univariate analyses of covariates were assessed for asso-
ciation with log-transformed charges and payments and significant variables were 
included in multivariate regression analysis. Base charges and payments include 
covariates at mean values and based on low risk characteristics. Results: In mul-
tivariate analysis, DD base charges at transplant were $155,906 (adjusted R2 0.314). 
BMI > 40 and BMI 35 – 39.9 was associated with an additional $13,3662 (p< 0.0001) 
and $4,107 (p= 0.005) at transplant, respectively. BMI 18.5 – 24.9 was attributed to 
significantly less charges of $2,168 (p= 0.016). Base reimbursements at transplant 
were $36,315 (adjusted R2 0.229). Elevated BMI was not attributed at any additional 
reimbursements, however BMI 18.5 – 24.9 had additional reimbursements of $660 
(p< 0.0001). For LD, base charges were $151,291(adjusted R2 0.312) and BMI 30 – 35.9 
was associated with an additional $3,675 (p= 0.018) at transplant. Base reimburse-
ments were $38,361(adjusted R2 0.239). Elevated BMI was not a significant independ-
ent factor additional reimbursement. ConClusions: Increased BMI is a significant 
factor in the amount of health resources utilized for kidney transplantation. While 
elevated BMI results in significant greater costs to hospitals, no additional reim-
bursement from Medicare was observed. These findings may play a factor in nega-
tive selection against candidates with higher BMI at the time of transplantation.
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objeCtives: Infantile haemangioma (IH) appears in the first few days of life, and 
develops over time. Certain types of IH cause significant functional impairment and 
aesthetic. The objective of this work was to estimate (in children under the age of 
two years) hospital stay length for IH previous to and subsequent to introduction of 
propranolol as haemangioma treatment. Methods: Analysis of the PMSI database 
covered two periods: the first previous to propranolol use (2006) and the second 
more recent (2011) during which use of propranolol became widespread. In the 
PMSI database, haemangioma can be found under primary diagnosis (or related) or 
associated, it is normal to carry out economic assessments on the PD. Results: In 
2006, 1,205 children were admitted to hospital for IH, thus generating 1,758 hospital 
stays. Day hospital admissions represent 24%. In 2011, 1,712 children were admitted 
to hospital for IH, thus generating 2,136 hospital stays,. Day hospital admissions 
represent 30%. The average length of stay, with haemangioma as primary diagno-
sis, decreased from 2.44days in 2006 to 1.16days on average in 2011, representing 
a 50% decrease. We note that DRG differ between 2006 and 2011, suggesting that 
the diagnosis is best determined. ConClusions: Infantile haemangioma has a 
significant medical and financial impact. A recent assessment conducted in France 
in five hospitals treating IH, considered that the average cost of treatment (accord-
ing to the health insurance fund) of children with haemangioma reached € 6,407.00 
on average. The highest expenditure item was hospitalisation at an average cost of 
€ 5,337.00 (equivalent to 83% of the total average cost). A reduction in the length of 
hospital stays, subsequent to propranolol use, of almost 50% as demonstrated by 
the PMSI, should have a significant effect on treatment costs.
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objeCtives: Psoriasis (PsO) is a chronic, recurrent, immune-mediated disease often 
treated with biologic therapies. However, understanding of prescription initiation of 
biologics for psoriasis is limited. The current study evaluates patient and provider 
characteristics in treatment-naïve PsO patients prescribed either exclusively oral 
or biologic-containing regimens. Methods: A retrospective database analysis was 
performed using Humedica electronic medical record data for adult patients with at 
least one diagnosis for PsO and no prior history of PsO or PsO-related therapy within 
12 months prior to index date. Eligible patients were classified based on initial 
prescription as (1) oral only or (2) biologics (including oral and biologics as combi-
nation treatment). Patients’ demographic characteristics, comorbidities, disease 
status, prescriber specialty, and prescriber preference of biologics were compared 
for across both groups. Wilcoxon rank-sum and chi-squared tests were applied to 
variables of ordinal and nominal measure, respectively. Logistic regression was 
conducted to determine the variables associated with likelihood of initiation of 
a biologic treatment. Results: A total of 2,373 patients met inclusion criteria. Of 
these patients, 1,166 (49%) were classified as obese, 856 (36%) were diagnosed with 
psoriatic arthritis (PsA) and 261 (11%) were diagnosed with rheumatoid arthritis 
(RA). Male patients (OR= 1.47) and patients with comorbid PsA (OR= 1.51) were sig-
nificantly more likely to be prescribed biologics compared to female patients and 
those without comorbid PsA, respectively. However, older patients (≥ 65 years) were 
significantly less likely (OR= 0.47) to be prescribed biologic regimens than patients 
aged 18-44 years. Differences in prescribing patterns by race, BMI, comorbid RA, and 
provider specialty were statistically insignificant. ConClusions: Male gender and 
comorbid PsA were associated with increased likelihood of initial biologic-based 
treatment for newly diagnosed PsO patients. Older age (≥ 65 years) was associated 
with a decreased likelihood of initial treatment with a biologic-containing regimen.
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No differences in improvements in HRQoL were observed with epratuzumab dur-
ing EMBLEM™, potentially due to short term treatment, small sample sizes and 
active SOC therapy. Sustained improvements were observed in the EMBLEM™ OLE, 
consistent with those in the ALLEVIATE RCTs.
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objeCtives: Obesity is associated with many health-related risk factors and is a 
significant economic burden on society. The objectives of this study were to exam-
ine the prevalence of patient-reported comorbidities, productivity loss and health-
related quality of life (HRQoL) across different BMI ranges. Methods: Overweight/
obese patients from the 2012 U.S. National Health and Wellness Survey, a nationally 
representative, online survey of 71,157 respondents aged ≥ 18 years, were catego-
rized and analyzed by their BMI: overweight (BMI> = 25 & < 30 kg/m2), obese class 
I (BMI> = 30 & < 35 kg/m2), obese class II (BMI> = 35 & < 40 kg/m2), and obese class 
III (BMI> = 40 kg/m2). Patients provided information on HRQoL (SF-36v2: mental 
and physical component summary (MCS, PCS) and SF-6D (health utility) scores), 
productivity loss (Work Productivity and Activity Impairment questionnaire) and 
comorbidities (sleep-difficulties, insomnia, pain, anxiety and depression) they expe-
rienced in the past 12 months. Results: Among 45,641 overweight/obese patients, 
49.8% were overweight, 27.9% were obese class I, 12.5% were obese class II, and 
9.8% were obese class III. The proportions of patients experiencing sleep-difficulties 
(overweight: 20.3%; obese class I: 24.6%; obese class II: 28.6%; obese class III: 35.3%), 
pain (overweight: 32.6%; obese class I: 38.1%; obese class II: 42.5%; obese class III: 
48.5%), insomnia, anxiety and depression increased along with BMI increase (all 
p< 0.001). MCS (overweight: 50.0; obese class I: 48.9; obese class II: 47.8; obese class 
III: 46.1), PCS (overweight: 51.1; obese class I: 48.8; obese class II: 46.5; obese class 
III: 43.0) and health utility scores declined with an increase in BMI (all p< 0.001). 
Among employed patients, overall work impairment increased as BMI increased 
(p< 0.001). ConClusions: Data suggests a greater prevalence of pain, depression, 
anxiety, and sleep problems as BMI increases. Increasing BMI is also associated with 
significantly worsening HRQoL. Successful obesity prevention and management 
may help improve patients’ quality of life and productivity.
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objeCtives: Current treatments for systemic lupus erythematosus (SLE) include 
corticosteroids (CS), immunosuppressants (IM), antimalarials (AM) and biologics. 
SLE treatments, in particular CS, are associated with adverse effects which impact 
tolerability and treatment-burden. This study sought to assess the use of CS in 
SLE, and the burden associated with this treatment class. Methods: Data were 
extracted from the Adelphi 2013 Lupus Disease-Specific Programme (a multina-
tional survey of clinical practice). Physicians completed Patient Record Forms (PRFs) 
and underwent face-to-face interviews; patients self-reported data including the 
EQ-5D, Work Productivity & Activity Impairment Index for SLE (WPAI-Lupus) and 
Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) in Patient Self-
Completion Records (PSCs). Patient eligibility was determined by physicians; disease 
activity and severity were based on physician and patient assessment. Results: 
Data were collected from rheumatologists in the US (n= 97), France (n= 37) and 
Germany (n= 35), including PRFs (550/200/207, respectively) and PSCs (303/109/149, 
respectively). 57%/84%/89% of patients in the US/France/Germany were receiving 
CS treatment. CS were perceived to be equal/superior to AM, IM and biologics in the 
ability to rapidly treat flare and pain but inferior in terms of safety/tolerability and 
inhibition of disease progression. More than half of patients had concerns regard-
ing CS treatment, mainly due to side-effects and fear of long-term use. Patients 
receiving CS had greater resource use (increased IM/biologic use, greater physi-
cian consultation and hospitalisation) and worse HRQoL and activity impairment 
vs non-CS patients (EQ-5D= 0.78 vs 0.87; FACIT-F= 34.41 vs 39.56; WPAI= 23.30 vs 
13.22), but were also associated with worse clinical status (more ‘moderate severe’ 
SLE, more ‘deteriorating’ disease state, more rash/pain/flaring/depression, greater 
organ system involvement). ConClusions: Although a major component of SLE 
standard of care, clear unmet needs are associated with CS use regarding HRQoL 
and resource use. Long-term safety and tolerability are also major areas of concern 
for both physicians and patients.
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objeCtives: Our objective was to determine costs of kidney transplant hospitaliza-
tion in charges billed and payments reimbursed by Medicare based on body mass 
index(BMI). Methods: Retrospective analysis of USRDS and Medicare Claims 
from 2004-2009 for primary Medicare beneficiaries of primary kidney transplant of 
deceased (DD) and living donors (LD) recipients. Subjects were excluded for multiple 
transplants, donor < 5 yo, and transplantation payment < 15,000 U.S. dollars. BMI 
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context, and consider alternatives to advance in RD coverage. Methods: A review 
of national and international literature was conducted with two main lines: papers 
available in bibliographic databases (MEDLINE, Cochrane, LILACS, among others), 
and governmental and non-governmental organizations documents, through search 
engines such as Google and Yahoo. Results: Relevant findings were arranged in a 
matrix that compare experiences according to different dimensions. Among them, 
there are two elements in the strategies classifications that must be emphasized: 
policy - or a legal framework for guidelines to address the problem - , and formal 
mechanisms of Health Technology Assessment (HTA) - that define the incorporation 
of new drugs to the health system -. The presence of these aspects, its development, 
and their distinctive features for each country, sets different financial scenarios 
for RD coverage. ConClusions: Chile is in an incipient stage of development in 
financing for DRD. International experience gives useful lessons for the develop-
ment of a funding policy for DRD in Chile. The way of structuring the policy frame-
work, technology assessment, funding and organization of the service offering, has 
an impact on the access of the population to DRD.
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objeCtives: The development of orphan drugs (OD) has substantially increased 
in the last decade. The objective of this study was to describe the trends in OD 
approvals from 2002 to present in the United States. Methods: We selected all 
OD approved between 2002 and 2013 from the FDA Orphan Products database. We 
extracted OD characteristics, especially all drug indications (with drug status as 
orphan/non orphan per therapeutic indication), the prevalence of the rare disease 
and the substance patent date. Frequency of approvals was described over time by 
therapeutic areas, prevalence of disease [rare vs. ultra rare (≤ 20 patients/million)] 
and duration of substance patent. Number of orphan indications by drug was also 
assessed over the last decade. Results: Since 2002, 143 OD were approved with 
162 indications for which the drugs were granted an orphan status (‘orphan indica-
tion’). The number of approved indications has increased by 76% when comparing 
2011-2013 period to 2008-2010 period. Oncology was found to be the major indica-
tion area, accounting for 36% of overall indications, followed by gastroenterology 
(8%) and hematology (7%). Across all indication areas, OD approvals proportion in 
oncology remained relatively stable over time, while other areas appeared randomly 
distributed over the years. About 12% of OD was approved in 2 or more indications, 
with a stable number over time. Half of approved OD displayed less than 7 years 
patent protection, or the period of exclusivity granted by the Orphan Drug Act. Ultra 
OD indications represented 27% of overall approvals, with 41% of ultra orphan indi-
cations approved in the last 3 years. ConClusions: This analysis confirmed the 
increase of OD approvals with a substantial proportion in oncology area between 
2002 and 2013. The 7 years exclusivity is critical for half of the products. No specific 
trends could be captured in the studied period.
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objeCtives: To understand real-world treatment patterns of CLL, the use 
of agents/regimens across all lines of therapy was evaluated in EU5 countries 
during the years 2010-2013. Methods: IPSOS Health care projected rituximab 
use for the treatment of CLL based on patient diaries. Representative panels of 
oncologists (N = 509) completed forms directly from reviews of patients’ charts 
and provided information on how they manage patients in everyday practice. A 
total of 104 physicians provided CLL patient information across first-, second-, 
and third-line CLL treatments. Important data such as age, comorbidities, and 
therapy goals were also abstracted. Results: According to the most recent 
annually projected data, a total of 37,119 patients with CLL are estimated to have 
been treated in the EU5 with any anticancer drug therapy between July 2012 and 
June 2013. The majority of these patients (23.1%) are estimated to have received 
fludarabine-cyclophosphamide-rituximab followed by bendamustine-rituximab 
(17.4%), chlorambucil (16.2%), fludarabine (7.2%), single-agent rituximab (5.8%), 
and chlorambucil-rituximab (5.6%). The data show higher rituximab monotherapy 
share in later lines of therapy for CLL (first-line, 0.3%; second-line, 8.2%, third-line 
or more, 22.1%) irrespective of age. Approved monoclonals (alemtuzumab, 2%, and 
ofatumumab, 4%) are not widely used in relapsed CLL. Our data also indicates 
that single-agent rituximab is now more commonly used in clinical practice than 
chlorambucil (22.1% vs 9.2%, respectively) as third-line treatment and above in 
patients with CLL. Among this subset of patients, diabetes is the most common 
comorbidity (13%). ConClusions: Rituximab is utilized either as a combinational 
or single-agent regimen across all lines of therapy in CLL and more commonly 
used in second-line treatment and above. No standard therapy is available for 
relapsed elderly or more comorbid CLL patients. This data may serve as real-world 
outcomes which can help in designing appropriate or interpreting outcomes of 
clinical trials programs.
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objeCtives: In most developed countries, policies incentivize manufacturers to 
invest in developing orphan drugs (OD) as the return on investment is unlikely. 
The objective of this study was to assess the overall performance of OD policies 
on development and revenue of OD. Methods: We identified on FDA website the 
yearly number of OD approved. We gathered revenue associated to OD from compa-
nies and individual products perspective through IMS sales database, Datamonitor 
reports, and companies’ websites and annual reports. We reviewed published OD 
forecasts. Results: In the US, the number of yearly approved drugs grew from less 
than 5 per year before 2000 to more than 20 in the last 3 years. In 2012, the turnover 
of OD business reached US$ 83 billion. The growth of this part of the pharmaceu-
tical market is very fast with a sales forecasting of US$ 127 billion in 2018 (153% 
compared to 2012). In 2010, 65 products generated more than US $100 million rev-
enue, 39 more than US$500 million, and 24 more than US $1 billion. Seven leading 
companies generate from US$9.9 to 1.7 billion yearly revenue with OD portfolio, 
representing a large proportion of the company turnover. This represents a serious 
burden on health insurance budget in most countries and will obviously continue 
to be subject to serious cost-containment measures. ConClusions: OD incentive 
policies reached their objective by contributing to a large increase of number of OD 
approved. Revenue associated to OD raises the question of appropriateness of OD 
policies as some products are among the top selling products. There is a need to 
review the OD policies and ensure it contribute to enhance development of product 
that would have not reached the market without solid incentive. Some authors 
proposed to revise the prevalence threshold to define OD.
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bACkgRound: Traditional health technology assessment is based on cost-effec-
tiveness, and is the foremost method used by decision-making bodies to inform 
funding decisions. This method is insufficient for expensive rare disease treatment 
decisions as it is premised on efficiency. Other factors guide the decision to fund 
rare disease treatments, including decision-maker values. With Canada’s drug 
costs being borne by the public, it is essential that societal values be understood by 
health ministries, particularly for rare diseases where large resources serve a small 
population. objeCtives: Identify the value-based criteria society feels are most 
important in decision making, the relative weight of these values, and whether 
rarity is strongly valued. Methods: A literature review revealed 13 values other 
than cost which have been used for value-based funding decisions. 2211 Canadians 
were surveyed online and asked to rank the values, and then perform an analytic 
hierarchy process of pairwise comparisons in order to attain both their rank and 
weight. Results: The factors selected in the top 5 for the majority of our subjects 
were: The ability of the drug to improve quality of life (66%) and quantity of life (50%), 
ability of drug to work (61%), severity of disease (60%) and safety (65%).These values 
were weighted 4-5 fold more important than those ranked lowest: unmet need, 
socioeconomic status, rarity, and adherence. Rarity had a relative weight of 0.02, the 
second least important value. Factors related to rare diseases such as severity of dis-
ease (0.12), Equity (0.07) and unmet need (0.04), were ranked higher. ConClusions: 
We have determined the most important factors Canadians feel should be used 
in value-based funding as well as their relative weight. These results have broad 
applications not limited to rare diseases. If rare diseases are to undergo value-based 
funding, our results indicate rarity alone may not be sufficient justification.
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objeCtives: This study aimed to evaluate the cost-utility of home based care versus 
no home based care policy of factor VIII and factor IX concentrate in Thai hemophilia 
A and B patients who had no inhibitor or less than 5 Bethesda units (BU). Methods: 
A Markov Model was used to evaluate the cost-utility of the two policies. The first 
policy was “no home bases care” where patients were treated with blood compo-
nents only when admitted at the hospital but without home treatment. The second 
policy was “home based care” where factors were prescribed and infused for treat-
ment of early bleeding episodes at home. Input parameters related to clinical and 
cost were obtained from primary data collection at the National Health Security 
Office, while patients’ quality of life was surveyed from mailed-questionnaire. Both 
costs and health outcomes were discounted at 3%. One-way and probabilistic sen-
sitivity analysis was performed to assess uncertainty surrounding model param-
eters. Results: Based on governmental perspective, “home based care” policy had 
cost saving in moderate and severe patients when compared with “no home based 
care” policy; while in mild hemophilia patients, the incremental cost-effectiveness 
ratio (ICER) was 80,542 THB or 2,684.73 US$ (30 THB:US$). ConClusions: At the 
ceiling threshold of one time of Gross Domestic Product (GDP) per capita (120,000 
THB per QALY gained), “home based care” policy was cost-effective when compared 
with “no home based care” policy.
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bACkgRound: In Chile, there is no official definition of Rare Disease (RD) yet. Each 
type of RD affects few people. However, taken together they are a public health 
problem. The subject is on the public agenda in form of a fund for Drugs for Rare 
Diseases (DRD). objeCtives: Review and describe RD financing strategies in major 
international experiences, in order to compare the situation of Chile in the global 
